Article info

Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus

Authors

  1. Correspondence to Dr Sarfaraz Hasni, Lupus Clinical Research, Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, BETHESDA, MD 20892, USA; sarfaraz.hasni{at}nih.gov
View Full Text

Citation

Hasni S, Temesgen-Oyelakin Y, Davis M, et al
Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus

Publication history

  • Received April 13, 2022
  • Accepted July 8, 2022
  • First published August 1, 2022.
Online issue publication 
October 12, 2022

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.